To further determine whether these drugs enhanced the antitumor effects of gefitinib in EGFR-WT NSCLC cells, we studied the effects of EZH2 and EGFR co-inhibition on the viability of A549 and H1299 cells using the CCK8 assay. This evidence concerns the gene EZH2 and non-small cell lung carcinoma.